Capital Expenditures - Protagonist Therapeutics Inc (NASDAQ:PTGX) - Alpha Spread

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 45.92 USD 2.57% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
Protagonist Therapeutics Inc?
Write Note

Protagonist Therapeutics Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Protagonist Therapeutics Inc
Capital Expenditures Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Protagonist Therapeutics Inc
NASDAQ:PTGX
Capital Expenditures
-$689k
CAGR 3-Years
6%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$858m
CAGR 3-Years
1%
CAGR 5-Years
-6%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
-$572m
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$965m
CAGR 3-Years
-14%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$481.8m
CAGR 3-Years
-12%
CAGR 5-Years
-47%
CAGR 10-Years
-23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$886.1m
CAGR 3-Years
-15%
CAGR 5-Years
-20%
CAGR 10-Years
-14%

See Also

What is Protagonist Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-689k USD

Based on the financial report for Jun 30, 2024, Protagonist Therapeutics Inc's Capital Expenditures amounts to -689k USD.

What is Protagonist Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
12%

Over the last year, the Capital Expenditures growth was -60%. The average annual Capital Expenditures growth rates for Protagonist Therapeutics Inc have been 6% over the past three years , 12% over the past five years .

Back to Top